img

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Research Report 2024

DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.
According to Mr Accuracy reports new survey, global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Segment by Type
Immune DTaP Vaccine
Therapy DTaP Vaccine

Segment by Application


Adult
Pediatric

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Overview
1.1 Product Overview and Scope of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
1.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type
1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value by Application: (2024-2034)
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2018-2029
1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2018-2029
1.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competition by Manufacturers
2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2018-2024)
2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price by Manufacturers (2018-2024)
2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Type & Application
2.7 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation and Trends
2.7.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue
2.7.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Retrospective Market Scenario by Region
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2018-2029
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2018-2024
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2024-2029
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018-2029
3.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018-2024
3.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2024-2029
3.4 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
3.4.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2029)
3.4.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
3.5.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2029)
3.5.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2029)
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2024-2029)
4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2029)
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2024)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2029)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2029)
5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024)
5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2024-2029)
5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2029)
5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2024)
5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2029)
5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi Pasteur
6.1.1 Sanofi Pasteur Corporation Information
6.1.2 Sanofi Pasteur Description and Business Overview
6.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.1.5 Sanofi Pasteur Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Protein Sciences Corporation
6.3.1 Protein Sciences Corporation Corporation Information
6.3.2 Protein Sciences Corporation Description and Business Overview
6.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.3.5 Protein Sciences Corporation Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Seqirus
6.5.1 Seqirus Corporation Information
6.5.2 Seqirus Description and Business Overview
6.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.5.5 Seqirus Recent Developments/Updates
6.6 Merck Sharp & Dohme Corp
6.6.1 Merck Sharp & Dohme Corp Corporation Information
6.6.2 Merck Sharp & Dohme Corp Description and Business Overview
6.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates
6.7 Astellas Pharma US
6.6.1 Astellas Pharma US Corporation Information
6.6.2 Astellas Pharma US Description and Business Overview
6.6.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.7.5 Astellas Pharma US Recent Developments/Updates
6.8 Pfizer Inc
6.8.1 Pfizer Inc Corporation Information
6.8.2 Pfizer Inc Description and Business Overview
6.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.8.5 Pfizer Inc Recent Developments/Updates
6.9 Johnson & Johnson
6.9.1 Johnson & Johnson Corporation Information
6.9.2 Johnson & Johnson Description and Business Overview
6.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.9.5 Johnson & Johnson Recent Developments/Updates
6.10 Lanzhou Institute of Biological Products Co., Ltd
6.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.10.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
6.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Corporation Information
6.11.2 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Description and Business Overview
6.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Emergent BioSolutions Inc
6.12.1 Emergent BioSolutions Inc Corporation Information
6.12.2 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Description and Business Overview
6.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
6.12.5 Emergent BioSolutions Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Chain Analysis
7.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
7.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
7.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
7.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
7.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
8 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
8.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
8.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
8.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
8.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) of Key Manufacturers (2018-2024)
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price (USD/Dose) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2018-2024)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2018-2024)
Table 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 27. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 28. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 32. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 33. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 37. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 38. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 42. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 43. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 47. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 48. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2018-2024)
Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2024-2029)
Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2018-2024)
Table 53. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2024)
Table 57. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Type (2018-2024)
Table 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Type (2024-2029)
Table 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Application (2018-2024)
Table 61. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Application (2024-2029)
Table 62. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2018-2024)
Table 63. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2024)
Table 67. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Application (2018-2024)
Table 69. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Application (2024-2029)
Table 70. Sanofi Pasteur Corporation Information
Table 71. Sanofi Pasteur Description and Business Overview
Table 72. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 73. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 74. Sanofi Pasteur Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 78. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Protein Sciences Corporation Corporation Information
Table 81. Protein Sciences Corporation Description and Business Overview
Table 82. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 83. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 84. Protein Sciences Corporation Recent Developments/Updates
Table 85. Novartis AG Corporation Information
Table 86. Novartis AG Description and Business Overview
Table 87. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 88. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 89. Novartis AG Recent Developments/Updates
Table 90. Seqirus Corporation Information
Table 91. Seqirus Description and Business Overview
Table 92. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 93. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 94. Seqirus Recent Developments/Updates
Table 95. Merck Sharp & Dohme Corp Corporation Information
Table 96. Merck Sharp & Dohme Corp Description and Business Overview
Table 97. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 98. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 99. Merck Sharp & Dohme Corp Recent Developments/Updates
Table 100. Astellas Pharma US Corporation Information
Table 101. Astellas Pharma US Description and Business Overview
Table 102. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 103. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 104. Astellas Pharma US Recent Developments/Updates
Table 105. Pfizer Inc Corporation Information
Table 106. Pfizer Inc Description and Business Overview
Table 107. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 108. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 109. Pfizer Inc Recent Developments/Updates
Table 110. Johnson & Johnson Corporation Information
Table 111. Johnson & Johnson Description and Business Overview
Table 112. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 113. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 114. Johnson & Johnson Recent Developments/Updates
Table 115. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 116. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 117. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 118. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 119. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 120. AstraZeneca Corporation Information
Table 121. AstraZeneca Description and Business Overview
Table 122. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 123. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 124. AstraZeneca Recent Developments/Updates
Table 125. Emergent BioSolutions Inc Corporation Information
Table 126. Emergent BioSolutions Inc Description and Business Overview
Table 127. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 128. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 129. Emergent BioSolutions Inc Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 133. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List
Table 134. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Table 135. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Table 136. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
Table 137. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2022 & 2029
Figure 4. Immune DTaP Vaccine Product Picture
Figure 5. Therapy DTaP Vaccine Product Picture
Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2022 & 2029
Figure 8. Adult
Figure 9. Pediatric
Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (2018-2029) & (US$ Million)
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2018-2029) & (K Doses)
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price (USD/Dose) & (2018-2029)
Figure 14. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 15. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players: Market Share by Revenue in 2022
Figure 18. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 20. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2018-2029)
Figure 21. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2018-2029)
Figure 22. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 23. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2018-2029)
Figure 25. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2018-2029)
Figure 26. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2018-2029)
Figure 32. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2018-2029)
Figure 33. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Indonesia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Thailand Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Malaysia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Philippines Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2018-2029)
Figure 44. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. U.A.E Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type (2018-2029)
Figure 54. Global Revenue Market Share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type (2018-2029)
Figure 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Type (2018-2029)
Figure 56. Global Sales Market Share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application (2018-2029)
Figure 57. Global Revenue Market Share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application (2018-2029)
Figure 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (USD/Dose) by Application (2018-2029)
Figure 59. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain
Figure 60. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries